Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
January 25, 2024 08:00 ET
|
Ocular Therapeutix, Inc.
SPA amendment expands eligibility criteria for SOL clinical trial Broadening of eligibility criteria anticipated to accelerate overall trial enrollment BEDFORD, Mass., Jan. 25, 2024 (GLOBE...
Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
December 18, 2023 16:01 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization...
Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock
December 13, 2023 22:09 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization...
Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
December 13, 2023 16:01 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization...
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
November 08, 2023 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update
November 07, 2023 16:01 ET
|
Ocular Therapeutix, Inc.
FDA Agrees to Overall Design of the First Pivotal Trial for AXPAXLI in Wet AMD under a Special Protocol Assessment; Expect First Subject Dosed by Year-End Top-line Data from U.S.-based HELIOS Trial...
Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
November 01, 2023 08:00 ET
|
Ocular Therapeutix, Inc.
The first subject expected to be dosed by year-end Company announces OTX-TKI trade name AXPAXLI BEDFORD, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a...
Ocular Therapeutix™ To Report Third Quarter 2023 Financial Results
October 24, 2023 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
October 03, 2023 16:01 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development and commercialization of innovative...
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
September 06, 2023 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...